Supernus Pharmaceuticals (SUPN) Set to Announce Quarterly Earnings on Wednesday

Supernus Pharmaceuticals (NASDAQ:SUPN) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Supernus Pharmaceuticals has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The company had revenue of $164.30 million during the quarter, compared to analyst estimates of $155.03 million. During the same period in the previous year, the company posted $0.43 earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was down 1.8% on a year-over-year basis. On average, analysts expect Supernus Pharmaceuticals to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $30.83 on Monday. The company’s 50-day moving average price is $31.72 and its two-hundred day moving average price is $28.80. Supernus Pharmaceuticals has a one year low of $21.99 and a one year high of $38.08.

Analyst Upgrades and Downgrades

Separately, Piper Sandler lowered their price target on shares of Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th.

Insiders Place Their Bets

In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $30.21, for a total transaction of $151,050.00. Following the sale, the vice president now owns 8,570 shares in the company, valued at approximately $258,899.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, VP Padmanabh P. Bhatt sold 5,000 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $30.21, for a total value of $151,050.00. Following the completion of the transaction, the vice president now owns 8,570 shares of the company’s stock, valued at approximately $258,899.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 12,364 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.31, for a total transaction of $436,572.84. Following the completion of the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at approximately $302,606.70. The disclosure for this sale can be found here. Insiders have sold a total of 35,739 shares of company stock worth $1,227,433 in the last quarter. Corporate insiders own 8.76% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.